Literature DB >> 1481183

Cardiovascular effects of fenoterol under conditions of hypoxaemia.

P Bremner1, C D Burgess, J Crane, D McHaffie, D Galletly, N Pearce, K Woodman, R Beasley.   

Abstract

BACKGROUND: The reason for the association of increased risk of death with fenoterol in patients with asthma in New Zealand is unknown but may relate to its cardiovascular effects. Most deaths from asthma occur outside hospital, where hypoxaemia is likely to be a complicating factor. The cardiovascular effects of fenoterol have been investigated therefore under conditions of normoxaemia and hypoxaemia.
METHOD: Eight healthy men were studied on two occasions. Measurements of heart rate, blood pressure, total electromechanical systole (QS2I), electrocardiographic QTc interval, cardiac index, stroke volume, and ejection fraction were made under conditions of normoxaemia and hypoxaemia (arterial oxygen saturation 90%) before and after administration of 800 micrograms of fenoterol by a metered dose inhaler. The order in which treatments were applied was according to a Latin square design.
RESULTS: Before inhalation of fenoterol hypoxaemia was associated with a significant increase in heart rate (8 beats/min) and QTc interval (15.6 ms). Under conditions of normoxaemia fenoterol caused a significant increase in heart rate (14.3 beats/min), systolic blood pressure (7.7 mm Hg), stroke volume (27.7 ml), cardiac index (1.6 1/min/m2), ejection fraction (11.48), and QTc interval (32.9 ms) and a fall in QS2I (-23.2 ms) and diastolic blood pressure (-8.4 mm Hg). Under conditions of hypoxaemia the changes after inhalation of fenoterol were similar to those recorded during normoxaemia; thus the effects of hypoxaemia and fenoterol were additive (heart rate 21.9 beats/min, QTc 43.5 ms with fenoterol and hypoxaemia).
CONCLUSION: The chronotropic and electrophysiological effects of fenoterol were enhanced by conditions of hypoxaemia.

Entities:  

Mesh:

Substances:

Year:  1992        PMID: 1481183      PMCID: PMC464060          DOI: 10.1136/thx.47.10.814

Source DB:  PubMed          Journal:  Thorax        ISSN: 0040-6376            Impact factor:   9.139


  18 in total

1.  Torsade De Pointes, an atypical ventricular tachycardia.

Authors:  D M Krikler; P V Curry
Journal:  Br Heart J       Date:  1976-02

2.  A critical review of the systolic time intervals.

Authors:  R P Lewis; S E Rittogers; W F Froester; H Boudoulas
Journal:  Circulation       Date:  1977-08       Impact factor: 29.690

3.  Lack of evidence for beta-2 receptor selectivity: a study of metaproterenol, fenoterol, isoproterenol, and epinephrine in patients with asthma.

Authors:  C D Burgess; H H Windom; N Pearce; S Marshall; R Beasley; R W Siebers; J Crane
Journal:  Am Rev Respir Dis       Date:  1991-02

4.  Recommendations regarding quantitation in M-mode echocardiography: results of a survey of echocardiographic measurements.

Authors:  D J Sahn; A DeMaria; J Kisslo; A Weyman
Journal:  Circulation       Date:  1978-12       Impact factor: 29.690

5.  Influence of ventilation and hypocapnia on sympathetic nerve responses to hypoxia in normal humans.

Authors:  V K Somers; A L Mark; D C Zavala; F M Abboud
Journal:  J Appl Physiol (1985)       Date:  1989-11

6.  Case-control study of prescribed fenoterol and death from asthma in New Zealand, 1977-81.

Authors:  N Pearce; J Grainger; M Atkinson; J Crane; C Burgess; C Culling; H Windom; R Beasley
Journal:  Thorax       Date:  1990-03       Impact factor: 9.139

7.  Cloning and expression of cDNA encoding a bovine adrenal cytochrome P-450 specific for steroid 21-hydroxylation.

Authors:  P C White; M I New; B Dupont
Journal:  Proc Natl Acad Sci U S A       Date:  1984-04       Impact factor: 11.205

8.  The cardio-toxicity of isoprenaline during hypoxia.

Authors:  J M Collins; D G McDevitt; R G Shanks; J G Swanton
Journal:  Br J Pharmacol       Date:  1969-05       Impact factor: 8.739

9.  Cardiopulmonary effects of fenoterol and salbutamol aerosols.

Authors:  M K Tandon
Journal:  Chest       Date:  1980-03       Impact factor: 9.410

10.  Correction of systolic time intervals for heart rate: a comparison of individual with population derived regression equations.

Authors:  S J Warrington; K Weerasuriya; C D Burgess
Journal:  Br J Clin Pharmacol       Date:  1988-08       Impact factor: 4.335

View more
  8 in total

1.  Current issues with beta2-adrenoceptor agonists: historical background.

Authors:  Anne E Tattersfield
Journal:  Clin Rev Allergy Immunol       Date:  2006 Oct-Dec       Impact factor: 8.667

Review 2.  Long-acting beta2 agonists in the management of stable chronic obstructive pulmonary disease.

Authors:  M Cazzola; C F Donner
Journal:  Drugs       Date:  2000-08       Impact factor: 9.546

3.  Inhibition by fenoterol of human eosinophil functions including beta2-adrenoceptor-independent actions.

Authors:  A Tachibana; M Kato; H Kimura; T Fujiu; M Suzuki; A Morikawa
Journal:  Clin Exp Immunol       Date:  2002-12       Impact factor: 4.330

Review 4.  Cardiovascular safety of beta(2)-adrenoceptor agonist use in patients with obstructive airway disease: a systematic review.

Authors:  Shelley R Salpeter
Journal:  Drugs Aging       Date:  2004       Impact factor: 3.923

5.  The rapid and effective administration of a beta 2-agonist to horses with heaves using a compact inhalation device and metered-dose inhalers.

Authors:  D B Tesarowski; L Viel; W N McDonell; M T Newhouse
Journal:  Can Vet J       Date:  1994-03       Impact factor: 1.008

6.  Cardiopulmonary interactions of salbutamol and hypoxaemia in healthy young volunteers.

Authors:  D G Kiely; R I Cargill; B J Lipworth
Journal:  Br J Clin Pharmacol       Date:  1995-10       Impact factor: 4.335

Review 7.  The beta 2-agonist controversy. Observations, explanations and relationship to asthma epidemiology.

Authors:  M R Sears; D R Taylor
Journal:  Drug Saf       Date:  1994-10       Impact factor: 5.606

8.  Evaluation of pharmacotherapy of obstructive airway diseases in the Montenegrin outpatient care: comparison with two Scandinavian countries.

Authors:  Natasha Duborija-Kovacevic; Milica Martinovic
Journal:  Multidiscip Respir Med       Date:  2012-06-21
  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.